



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 7/48, 35/78	A1	(11) International Publication Number: WO 98/20852 (43) International Publication Date: 22 May 1998 (22.05.98)
(21) International Application Number: PCT/US97/18981 (22) International Filing Date: 27 October 1997 (27.10.97) (30) Priority Data: 60/032,048 12 November 1996 (12.11.96) US (71) Applicant (for all designated States except US): PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): MUNDEN, James, W. [US/US]; 7404 Arborcrest Street, Portage, MI 49024 (US). (74) Agent: YANG, Lucy, X.; Pharmacia & Upjohn Company, Intellectual Property Legal Services, 301 Henrietta Street, Kalamazoo, MI 49001 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PHARMACEUTICAL COMPOSITIONS CONTAINING KUKUI NUT OIL (57) Abstract <p>The present invention provides pharmaceutical compositions comprising an effective amount of dermatopharmaceutical active agent, kukui nut oil and a pharmaceutically acceptable base which comprises ingredients selected from the group consisting of propylene glycol, glycerin, xanthin gum, methyl paraben, propyl paraben, stearic acid, menthyl lactate, cetearyl alcohol (and) ceteareth 20, polyoxyl 40 stearate, glyceryl stearate (and) PEG-100 stearate, isopropyl myristate, isopropyl alcohol, oleyl alcohol, oleic acid, dimethicone, or C₁₂-C₁₅ alcohols benzoate and purified water. The inclusion of kukui nut oil acts in synergy as an adjunct to the therapeutic agent to promote the alleviation of the medical condition being treated.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PHARMACEUTICAL COMPOSITIONS CONTAINING KUKUI NUT OIL

FIELD OF THE INVENTION

The present invention relates to pharmaceutical compositions which are
5 useful for the treatment of human skin disorder. The compositions comprise, a
pharmaceutically acceptable base, an active dermopharmaceutical agent and kukui
nut oil.

BACKGROUND OF THE INVENTION

10 Topical application of drugs to the skin surface has been used since antiquity
to treat diseases of the skin. Skin has the tendency to dry out when exposed to
conditions of low humidity or to an extended period of time in chemicals. A common
finding in patients with skin diseases is the high incidence of dry skin, i.e. the
inflamed skin surface feels rough to the touch. See: "Bioengineering of the Skin:
15 Water and the Stratum Corneum", Chapter 8. CRC Press, Inc., London, pp. 87-132
(1994). Although the treatment of human skin with various agents has been
undertaken for many years in the cosmetic field with the goal to keep the skin in a
smooth supple condition, the consideration has never been taken to mind when
dermopharmaceutical compositions are proposed.

20 On the other hand, it is known that mineral hydrocarbons (petrolatum
derivatives) are extensively used in pharmaceutical and cosmetic compositions as
well as in various food products. Recently, there are safety concerns over the use of
these mineral hydrocarbons in pharmaceutical, cosmetic, and food products.

Accordingly, the object of the present invention is to provide therapeutically
25 active compositions for the treatment of human skin diseases.

More particularly, the object of the present invention is to provide therapeutic
compositions which have additional skin care benefits to the patients whose skin
disorders are accompanied by dryness which demand treatments beyond solely using
topically applied drugs.

30 Another object of the present invention is to provide a pharmaceutically
acceptable base containing natural oils as an alternative to mineral oil in
formulating therapeutically active compositions.

After various searches on a large number of substances, it has been
discovered that incorporation of kukui nut oil into certain stable cream, lotion, or
35 ointment bases which contain an effective amount of active dermopharmaceutical
agent, such as a corticosteroid, antibiotic, antihistamine, antifungal, anesthetic, or

analgesic, have a particularly pronounced synergic effect.

Experiments have also been conducted to determine if various natural oils could be substituted for mineral oil one to one in typical oil and water emulsion in the pharmaceutical and cosmetic compositions. Based on the studies, however, it is determined that kukui nut oil is one of several vegetable oils which are non-viable alternatives to mineral oil in formulating typical cosmetic and pharmaceutical creams or lotions. Surprisingly and unexpectedly, the compositions of the present invention provide pharmaceutically acceptable bases containing kukui nut oil which can be used as active dermopharmaceutical agent carriers.

10

INFORMATION DISCLOSURE

Kukui nut tree, is a native tree in all countries from western Polynesia to southern Asia and is generally found in woods of lower mountain zone, web gushes and valleys, ravines and hanging valleys of tropics and subtropics. In the United States, the kukui tree is found in all islands of Hawaii. Certain medicinal and other uses of various portions of the kukui nut tree or its nut have been reported, particularly in native Hawaiian medicine, the kukui nut has many uses.

Hawaii Dental Journal, pages 8 and 13 (1986), discloses several uses of kukui nut tree. Kukui flowers, baked kukui nut and sugarcane mixture are used for stomachache and bowel disorders. Kukui bark is used in herbal tea. Chronic ulcers and scrofula are treated with mixture containing kukui meat and kukui nut cooled in kukui leaves. Sap from the kukui nut tree is used to treat bad breath and coated tongue. The juice of the kukui fruit are used as a mouthwash, for the treatment of a fungal infection thrush or moniliasis, and for other superficial internal oral lesions.

U.S. Patent No. 5,213,798 discloses the use of the active ingredient present in the liquid obtained from the green hull of the kukui nut as an antiviral pharmaceutical agent.

U.S. Patent No.4,525,344 discloses a combination skin care and shaving composition containing kukui nut oil.

U.S. Patent No.4,525,344 discloses suntanning oil formulation containing kukui nut oil.

Additional references of general interest include the following:

H. Ako et al., *J. Soc. Cosmet. Chem.*, Vol. 44, pp. 239-247 (1993); I. A. Abbott and C. Shimazu, *J. Ethnopharm.*, Vol. 14, pp. 213-222, (1985); J. Brod et al., *International journal of Cosmetic Science*, Vol. 10, pp. 149-159 (1988); and K. Klein, *Cosmetics & Toiletries*, Vol. 106, pp. 87-88 (1991).

While certain properties of the kukui nut are known, there has been no reports or suggestions regarding the use of kukui nut oil in combination with active pharmaceutical agents for the treatment of the skin diseases.

5

SUMMARY OF THE INVENTION

This invention provides a pharmaceutical composition comprising:

a) an effective amount of dermatopharmaceutical active agent, b) about 1.0% to about 10% of kukui nut oil by weight of the total composition, and c) up to about 98% by weight of the total composition of a pharmaceutically acceptable base which
10 comprises ingredients selected from the group consisting of propylene glycol, glycerin, xanthin gum, methyl paraben, propyl paraben, stearic acid, menthyl lactate, cetearyl alcohol (and) cetareth 20, polyoxyl 40 stearate, glyceryl stearate (and) PEG-100 stearate, isopropyl myristate, isopropyl alcohol, oleyl alcohol, oleic acid, dimethicone, or C₁₂- C₁₅ alcohols benzoate and purified water.

15

The inclusion of kukui nut oil acts in synergy as an adjunct to the therapeutic agent to promote the alleviation of the medical condition being treated.

DETAILED DESCRIPTION OF THE INVENTION

Kukui nut oil, extracted from the nuts of kukui nut trees, has been used for
20 hundreds of years by native Hawaiians to treat a variety of ailments. Of particular note is the application to skin disorders. The rapid penetration of the oil into the skin has been shown to bring rapid, soothing relief for superficial burns, chapped skin, and minor skin diseases. Application prior to exposure of the skin to challenges such as wind and sun also help prevent skin damage from occurring. The
25 inclusion of kukui nut oil acts in synergy as an adjunct to the therapeutic agent to promote the alleviation of the medical condition being treated. The results of these combinations against inflamed, infected, or other skin disorders are more effective than each of the components, the kukui nut oil, on the one hand, or active dermatopharmaceutical agents, on the other hand, when the latter are taken
30 separately, at comparable concentrations.

The pharmaceutical compositions of this invention may be prepared by combining an active dermatopharmaceutical agent with kukui nut oil, in a pharmaceutically acceptable base.

The term "kukui nut oil " refers to the fat obtained from the nut of a kukui
35 tree, also known as *Aleurites moluccana* or the candlenut tree. An example of such oil is the natural kukui nut oil, sold under the trade name "Oils of Aloha TM" by the

Hawaiian Kukui Nut Company.

The kukui nut oil is present in the compositions of this invention at a concentration of from about 0.5% to about 10%, preferably at a concentration of about 2%.

5 The term "active dermopharmaceutical agents" refers to corticosteroid, analgesics, anesthetics, antibiotics, antihistamines, and antifungals, particularly referring to corticosteroids such as hydrocortisone.

10 The active dermopharmaceutical agents are present in the compositions at a normal range commonly known and well accepted by physicians of ordinary skill and those skilled in the pharmaceutical field. For example, the normal range of hydrocortisone in topical products is at a concentration of from 0.5 % to 2.5 % by weight; the normal range of anesthetic such as lidocaine in topical products is at a concentration of from 0.5 % to 4 % by weight, higher concentrations are present in some prescription (Rx) products; the normal range of antihistamine or
15 diphenhydramine in topical products is at a concentration of from 0.5 % to 2.5 % by weight; the normal range of zinc oxide in topical products is at a concentration of from 1 % to 25 % by weight; and the normal range of urea in topical products is at a concentration of from 5 % to 10 % by weight.

20 The term "pharmaceutically acceptable base" refers to ingredients which are acceptable in the pharmaceutical sciences as a drug carrier. For the present invention, the pharmaceutically acceptable base comprises ingredients selected from the group consisting of propylene glycol, glycerin, xanthin gum, methyl paraben, propyl paraben, stearic acid, menthyl lactate, cetearyl alcohol (and) ceteareth 20, polyoxyl 40 stearate, glyceryl stearate (and) PEG-100 stearate, isopropyl myristate,
25 isopropyl alcohol, oleyl alcohol, oleic acid, dimethicone or C₁₂- C₁₅ alcohols benzoate, and purified water. All these ingredients are commercially available and do not require any special preparation before use.

The pharmaceutical compositions of this invention can optionally contain conventional coloring agents, fragrances, stabilizers and thickening agents.

30 The pharmaceutical compositions of this invention are provided in a form intended to be applied topically such as, for example, lotion, thickened lotion, gel cream, milk, ointment, or vesicular dispersion, preferably in the forms of lotion and cream.

35 The term "skin disorders" or "skin diseases" means the diseases associated with inflammation, infections such as fungal and bacterial infections, dermatitis, psoriasis, eczema, and allergies. Such diseases and conditions are well known and

readily diagnosed by physicians of ordinary skill.

The term "Promulgen D" refers to a mixture of cetearyl alcohol and ceteareth 20 known under CTFA terminology as "cetearyl alcohol (and) ceteareth 20".

Promulgen D is sold under the trademark PROMULGEN®D.

- 5 The term "Arlacel 165" refers to a mixture of glyceryl stearate and PEG-100 stearate known under the CTFA nomenclature as "glyceryl stearate (and) PEG-100 stearate". Arlacel 165 is sold under the trademark ARLACEL® 165.

- The term "Finsolv TN" refers to a mixture of C₁₂- C₁₅ alcohols benzoate known under CTFA nomenclature as "C₁₂- C₁₅ alcohols benzoate". Finsolv TN is
10 sold under the trademark FINSOLV TN.

CTFA refers to the Cosmetic, Toiletries, and Fragrances Association.

The term "q.s." refers to quantum sufficit or as much as being sufficient.

The term "q.s. ad" refers to addition of a sufficient quantity of that material to bring the final composition to the specified volume.

- 15 All temperatures are in degrees Centigrade.

The pharmaceutical compositions of this invention are seen more fully by the examples given below.

LOTION BASE EXAMPLE # 1

20	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
	Glycerin NF	2.0 %
	Xanthan gum NF	0.2 %
	Methyl paraben NF	0.2 %
	Propyl paraben NF	0.1 %
25	Promulgen D	3.0 %
	Arlacel 165	10.0 %
	Isopropyl Myristate	5.0 %
	Oleyl Alcohol	5.0 %
	Finsolv TN	6.0 %
30	Kukui Nut Oil	2.0 %
	Dimethicone	2.0 %
	Purified Water	q.s. ad 100.0 %

- Heat a portion of the water to 65° C. Disperse the xanthan gum in the glycerin and add to the water with agitation. Melt the Promulgen, Arlacel, isopropyl
35 myristate, oleyl alcohol, Finsolv TN, and kukui nut oil together at 65° C. Dissolve the parabens in the oils. Then add the oil phase to the water phase with rapid

mixing. Remove heat and add the volatile silicone. Rapidly cool to 40° C once the emulsion is formed. Continue mixing until room temperature is reached. Perform final q.s.

5 LOTION BASE EXAMPLE # 2

	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
	Propylene Glycol	2.0 %
	Xanthan gum NF	0.2 %
	Methyl paraben NF	0.2 %
10	Propyl paraben NF	0.1 %
	Promulgen D	3.0 %
	Arlacel 165	10.0 %
	Isopropyl Myristate	5.0 %
	Oleyl Alcohol	5.0 %
15	Finsolv TN	6.0 %
	Kukui Nut Oil	2.0 %
	Dimethicone	2.0 %
	Purified Water	q.s. ad 100.0 %

Heat a portion of the water to 65° C. Disperse the xanthan gum in the
 20 propylene glycol and add to the water with agitation. Melt the Promulgen, Arlacel, isopropyl myristate, oleyl alcohol, Finsolv TN, and kukui nut oil together at 65° C. Dissolve the parabens in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the volatile silicone. Rapidly cool to 40° C once the emulsion is formed. Continue mixing until room temperature is reached.
 25 Perform final q.s.

LOTION BASE EXAMPLE # 3

	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
	Propylene Glycol	2.0 %
30	Xanthan gum NF	0.2 %
	Methyl paraben NF	0.2 %
	Propyl paraben NF	0.1 %
	Promulgen D	3.0 %
	Arlacel 165	10.0 %
35	Isopropyl Myristate	5.0 %
	Oleic Acid	5.0 %

Finsolv TN	6.0 %
Kukui Nut Oil	2.0 %
Dimethicone	2.0 %
Purified Water	q.s. ad 100.0 %

- 5 Heat a portion of the water to 65° C. Disperse the xanthan gum in the propylene glycol and add to the water with agitation. Melt the Promulgen, Arlacel, isopropyl myristate, oleic acid, Finsolv TN, and kukui nut oil together at 65° C. Dissolve the parabens in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the volatile silicone. Rapidly cool to 40° C once
- 10 the emulsion is formed. Continue mixing until room temperature is reached. Perform final q.s.

CREAM BASE EXAMPLE # 4

	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
15	Glycerin NF	2.0 %
	Methyl paraben NF	0.2 %
	Propyl paraben NF	0.1 %
	Stearic Acid NF	8.0 %
	Polyoxyl 40 Stearate NF	4.0 %
20	Arlacel 165	10.0 %
	Isopropyl Myristate	5.0 %
	Oleyl Alcohol	5.0 %
	Kukui Nut Oil	2.0 %
	Dimethicone	2.0 %
25	Purified Water	q.s. ad 100.0 %

- Heat a portion of the water to 65° C. Disperse the methyl paraben in the glycerin and add to the water with agitation. Melt the stearic acid, Arlacel, polyoxyl 40 stearate, isopropyl myristate, oleyl alcohol, and kukui nut oil together at 65° C. Dissolve the propyl paraben in the oils. Then add the oil phase to the water phase
- 30 with rapid mixing. Remove heat and add the volatile silicone. Rapidly cool to 40° C once the emulsion is formed. Continue mixing until room temperature is reached. Perform final q.s.

CREAM BASE EXAMPLE # 5

	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
35	Glycerin NF	2.0 %

	Methyl paraben NF	0.2 %
	Propyl paraben NF	0.1 %
	Stearic Acid NF	8.0 %
	Polyoxyl 40 Stearate NF	4.0 %
5	Arlacel 165	10.0 %
	Isopropyl Myristate	5.0 %
	Oleic Acid	5.0 %
	Kukui Nut Oil	2.0 %
	Dimethicone	2.0 %
10	Purified Water	q.s. ad 100.0 %

Heat a portion of the water to 65° C. Disperse the methyl paraben in the glycerin and add to the water with agitation. Melt the stearic acid, Arlacel, polyoxyl 40 stearate, isopropyl myristate, oleic acid, and kukui nut oil together at 65° C. Dissolve the propyl paraben in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the volatile silicone. Rapidly cool to 40° C once the emulsion is formed. Continue mixing until room temperature is reached. Perform final q.s.

CREAM BASE EXAMPLE # 6

20	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
	Propylene Glycol	2.0 %
	Methyl paraben NF	0.2 %
	Propyl paraben NF	0.1 %
	Stearic Acid NF	8.0 %
25	Polyoxyl 40 Stearate NF	4.0 %
	Arlacel 165	10.0 %
	Isopropyl Myristate	5.0 %
	Oleyl Alcohol	5.0 %
	Kukui Nut Oil	2.0 %
30	Dimethicone	2.0 %
	Purified Water	q.s. ad 100.0 %

Heat a portion of the water to 65° C. Disperse the methyl paraben in the propylene glycol and add to the water with agitation. Melt the stearic acid, Arlacel, polyoxyl 40 stearate, isopropyl myristate, oleyl alcohol, and kukui nut oil together at 65° C. Dissolve the propyl paraben in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the volatile silicone. Rapidly cool

to 40° C once the emulsion is formed. Continue mixing until room temperature is reached. Perform final q.s.

LOTION BASE EXAMPLE # 7

	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
5	Propylene Glycol	2.0 %
	Methyl paraben NF	0.2 %
	Propyl paraben NF	0.1 %
	Polyoxyl 40 Stearate NF	4.0 %
10	Arlacel 165	10.0 %
	Isopropyl Myristate	5.0 %
	Isostearyl Alcohol	5.0 %
	Kukui Nut Oil	2.0 %
	Dimethicone	2.0 %
15	Fragrance	q.s.
	Purified Water	q.s. ad 100.0 %

Heat a portion of the water to 65° C. Disperse the methyl paraben in the propylene glycol and add to the water with agitation. Melt the Arlacel, polyoxyl 40 stearate, isopropyl myristate, isostearyl alcohol, and kukui nut oil together at 65° C.

- 20 Dissolve the propyl paraben in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the volatile silicone. Rapidly cool to 40° C once the emulsion is formed. Add fragrance. Continue mixing until room temperature is reached. Perform final q.s.

25 CREAM BASE EXAMPLE # 8

	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
	Propylene Glycol	2.0 %
	Methyl paraben NF	0.2 %
	Propyl paraben NF	0.1 %
30	Stearic Acid NF	8.0 %
	Polyoxyl 40 Stearate NF	4.0 %
	Arlacel 165	10.0 %
	Isopropyl Myristate	5.0 %
	Isostearyl Alcohol	5.0 %
35	Kukui Nut Oil	2.0 %
	Dimethicone	2.0 %

Purified Water q.s. ad 100.0 %

Heat a portion of the water to 65° C. Disperse the methyl paraben in the propylene glycol and add to the water with agitation. Melt the stearic acid, Arlacel, polyoxyl 40 stearate, isopropyl myristate, oleyl alcohol, and kukui nut oil together at 65° C. Dissolve the propyl paraben in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the volatile silicone. Rapidly cool to 40° C once the emulsion is formed. Continue mixing until room temperature is reached. Perform final q.s.

10

CREAM BASE EXAMPLE # 9

	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
	Propylene Glycol	2.0 %
	Methyl paraben NF	0.2 %
15	Propyl paraben NF	0.1 %
	Stearic Acid NF	8.0 %
	Polyoxyl 40 Stearate NF	4.0 %
	Arlacel 165	10.0 %
	Isopropyl Myristate	5.0 %
20	Isostearyl Alcohol	5.0 %
	Kukui Nut Oil with Fragrance	2.0 %
	Dimethicone	2.0 %
	Purified Water	q.s. ad 100.0 %

Heat a portion of the water to 65° C. Disperse the methyl paraben in the propylene glycol and add to the water with agitation. Melt the stearic acid, Arlacel, polyoxyl 40 stearate, isopropyl myristate, isostearyl alcohol, and kukui nut oil together at 65° C. Dissolved the propyl paraben in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the volatile silicone. Rapidly cool to 40° C once the emulsion is formed. Continue mixing until room temperature is reached. Perform final q.s.

30

CREAM BASE EXAMPLE # 10

	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
	Propylene Glycol	2.0 %
35	Methyl paraben NF	0.2 %
	Propyl paraben NF	0.1 %

	Stearic Acid NF	8.0 %
	Polyoxyl 40 Stearate NF	4.0 %
	Arlacel 165	10.0 %
	Isopropyl Myristate	5.0 %
5	Isostearyl Alcohol	5.0 %
	Kukui Nut Oil	2.0 %
	Dimethicone	2.0 %
	Petals Fragrance G7042	0.3 %
	Purified Water	q.s. ad 100.0 %
10	Heat a portion of the water to 65° C. Disperse the methyl paraben in the propylene glycol and add to the water with agitation. Melt the stearic acid, Arlacel, polyoxyl 40 stearate, isopropyl myristate, isostearyl alcohol, and kukui nut oil together at 65° C. Dissolve the propyl paraben in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the volatile silicone and	
15	the fragrance. Perform the final q.s. Rapidly cool to 40° C once the emulsion is formed. Continue mixing until room temperature is reached.	

CREAM BASE EXAMPLE BASE # 11

	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
20	Propylene Glycol	2.0 %
	Methyl paraben NF	0.2 %
	Propyl paraben NF	0.1 %
	Promulgen D	8.0 %
	Polyoxyl 40 Stearate NF	4.0 %
25	Arlacel 165	10.0 %
	Isopropyl Myristate	5.0 %
	Isostearyl Alcohol	5.0 %
	Kukui Nut Oil	2.0 %
	Fragrance (optional)	q.s.
30	Purified Water	q.s. ad 100.0 %

35	Heat a portion of the water to 65° C. Disperse the methyl paraben in the propylene glycol and add to the water with agitation. Melt the Promulgen D, Arlacel, polyoxyl 40 stearate, isopropyl myristate, isostearyl alcohol, and kukui nut oil together at 65° C. Dissolve the propyl paraben in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the fragrance. Perform the final q.s. Rapidly cool to 40° C once the emulsion is formed. Continue mixing	
----	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

until room temperature is reached.

LOTION BASE EXAMPLE # 12

	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
5	Propylene Glycol	2.0 %
	Methyl paraben NF	0.2 %
	Propyl paraben NF	0.1 %
	Promulgen D	2.0 %
	Polyoxyl 40 Stearate NF	4.0 %
10	Arlacel 165	10.0 %
	Isopropyl Myristate	5.0 %
	Isostearyl Alcohol	5.0 %
	Kukui Nut Oil	2.0 %
	Dimeticone	2.0 %
15	Fragrance (optional)	q.s.
	Purified Water	q.s. ad 100.0 %

Heat a portion of the water to 65° C. Disperse the methyl paraben in the propylene glycol and add to the water with agitation. Melt the Promulgen D, Arlacel, polyoxyl 40 stearate, isopropyl myristate, isostearyl alcohol, and kukui nut oil together at 65° C. Dissolve the propyl paraben in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the fragrance and the volatile silicone. Perform the final q.s. Rapidly cool to 40° C once the emulsion is formed. Continue mixing until room temperature is reached.

25 LOTION BASE EXAMPLE # 13

	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
	Propylene Glycol	2.0 %
	Methyl paraben NF	0.2 %
	Propyl paraben NF	0.1 %
30	Promulgen D	4.0 %
	Polyoxyl 40 Stearate NF	4.0 %
	Arlacel 165	10.0 %
	Isopropyl Myristate	5.0 %
	Isostearyl Alcohol	5.0 %
35	Kukui Nut Oil	2.0 %
	Dimeticone	2.0 %

Fragrance (optional)	q.s.
Purified Water	q.s. ad 100.0 %

Heat a portion of the water to 65° C. Disperse the methyl paraben in the propylene glycol and add to the water with agitation. Melt the Promulgen D, Arlacel, polyoxyl 40 stearate, isopropyl myristate, isostearyl alcohol, and kukui nut oil together at 65° C. Dissolve the propyl paraben in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the fragrance and volatile silicone. Perform the final q.s. Rapidly cool to 40° C once the emulsion is formed. Continue mixing until room temperature is reached.

10

CREAM BASE WITH HYDROCORTISONE EXAMPLE # 14

	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
	Propylene Glycol	2.0 %
	Hydrocortisone	1.0 %
15	Methyl paraben NF	0.2 %
	Propyl paraben NF	0.1 %
	Promulgen D	8.0 %
	Polyoxyl 40 Stearate NF	4.0 %
	Arlacel 165	10.0 %
20	Isopropyl Myristate	5.0 %
	Isostearyl Alcohol	5.0 %
	Kukui Nut Oil	2.0 %
	Dimethicone	1.0 %
	Fragrance (optional)	q.s.
25	Purified Water	q.s. ad 100.0 %

Heat a portion of the water to 65° - 70° C. Disperse the methyl paraben in the propylene glycol and add to the water with agitation. Add the polyoxyl 40 stearate and dissolve. Add the hydrocortisone and disperse using a high shear mixer or similar. Melt the Promulgen D, Arlacel, isopropyl myristate, isostearyl alcohol, and kukui nut oil together at 65° - 70° C. Dissolve the propyl paraben in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the dimethicone and fragrance. Perform the final q.s. Rapidly cool to 40° C once the emulsion is formed. Continue mixing until room temperature is reached.

35

LOTION BASE WITH LIDOCAINE HYDROCHLORIDE EXAMPLE #15

	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
	Propylene Glycol	2.0 %
	Lidocaine Hydrochloride	4.0 %
5	Methyl paraben NF	0.2 %
	Propyl paraben NF	0.1 %
	Promulgen D	6.0 %
	Polyoxyl 40 Stearate NF	4.0 %
	Arlacel 165	10.0 %
10	Isopropyl Myristate	5.0 %
	Isostearyl Alcohol	5.0 %
	Kukui Nut Oil	2.0 %
	Dimethicone	1.0 - 2.0 %
	Fragrance (optional)	q.s.
15	Purified Water	q.s. ad 100.0 %

Heat a portion of the water to 65° - 70° C. Disperse the methyl paraben in the propylene glycol and add to the water with agitation. Add the lidocaine and dissolve. Melt the polyoxyl 40 stearate, Promulgen D, Arlacel, isopropyl myristate, isostearyl alcohol, and kukui nut oil together at 65°- 70° C. Dissolve the propyl paraben in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the dimethicone and fragrance. Perform the final q.s. Rapidly cool to 40° C once the emulsion is formed. Continue mixing until room temperature is reached.

25 LOTION BASE WITH LIDOCAINE HYDROCHLORIDE EXAMPLE #16

	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
	Propylene Glycol	2.0 %
	Lidocaine Hydrochloride	4.0 %
	Methyl paraben NF	0.2 %
30	Propyl paraben NF	0.1 %
	Promulgen D	4.0 %
	Polyoxyl 40 Stearate NF	2.0 %
	Arlacel 165	10.0 %
	Isopropyl Myristate	5.0 %
35	Isostearyl Alcohol	5.0 %
	Kukui Nut Oil	2.0 %

Dimethicone	1.0 %
Fragrance (optional)	q.s.
Purified Water	q.s. ad 100.0 %

- Heat a portion of the water to 65° - 70° C. Disperse the methyl paraben in the propylene glycol and add to the water with agitation. Add the lidocaine and dissolve. Melt the polyoxyl 40 stearate, Promulgen D, Arlacel, , isopropyl myristate, isostearyl alcohol, and kukui nut oil together at 65° - 70° C. Dissolve the propyl paraben in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the dimethicone and fragrance. Perform the final q.s.
- 10 Rapidly cool to 40° C once the emulsion is formed. Continue mixing until room temperature is reached.

LOTION BASE WITH DIPHENHYDRAMINE HYDROCHLORIDE EXAMPLE # 17

	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
15	Propylene Glycol	2.0 %
	Diphenhydramine Hydrochloride USP	2.0 %
	Methyl paraben NF	0.2 %
	Propyl paraben NF	0.1 %
	Promulgen D	6.0 %
20	Polyoxyl 40 Stearate NF	4.0 %
	Arlacel 165	10.0 %
	Isopropyl Myristate	5.0 %
	Isostearyl Alcohol	5.0 %
	Kukui Nut Oil	2.0 %
25	Dimethicone	1.0 %
	Fragrance (optional)	q.s.
	Purified Water	q.s. ad 100.0 %

- Heat a portion of the water to 65° - 70° C. Disperse the methyl paraben in the propylene glycol and add to the water with agitation. Add the diphenhydramine and dissolve. Melt the polyoxyl 40 stearate, Promulgen D, Arlacel, , isopropyl myristate, isostearyl alcohol, and kukui nut oil together at 65° - 70° C. Dissolve the propyl paraben in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the dimethicone and fragrance. Perform the final q.s. Rapidly cool to 40° C once the emulsion is formed. Continue mixing until room
- 35 temperature is reached.

LOTION BASE WITH DIPHENHYDRAMINE HYDROCHLORIDE
AND ZINC OXIDE EXAMPLE #18

	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
	Propylene Glycol	2.0 %
5	Diphenhydramine Hydrochloride	2.0 %
	Zinc Oxide	2.0 %
	Methyl paraben NF	0.2 %
	Propyl paraben NF	0.1 %
	Promulgen D	6.0 %
10	Polyoxyl 40 Stearate NF	4.0 %
	Arlacel 165	10.0 %
	Isopropyl Myristate	5.0 %
	Isostearyl Alcohol	5.0 %
	Kukui Nut Oil	2.0 %
15	Dimethicone	1.0 %
	Fragrance (optional)	q.s.
	Purified Water	q.s. ad 100.0 %

Heat a portion of the water to 65° - 70° C. Disperse the methyl paraben in the propylene glycol and add to the water with agitation. Add the diphenhydramine and dissolve. Dispense the zinc oxide in the aqueous solution. Melt the polyoxyl 40 stearate, Promulgen D, Arlacel, isopropyl myristate, isostearyl alcohol, and kukui nut oil together at 65°- 70° C. Dissolve the propyl paraben in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the dimethicone and fragrance. Perform the final q.s. Rapidly cool to 40° C once the emulsion is formed. Continue mixing until room temperature is reached.

CREAM BASE WITH UREA EXAMPLE # 19

	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
	Propylene Glycol	2.0 %
30	Urea	10.0 %
	Methyl paraben NF	0.2 %
	Propyl paraben NF	0.1 %
	Promulgen D	8.0 %
	Polyoxyl 40 Stearate NF	4.0 %
35	Arlacel 165	10.0 %
	Isopropyl Myristate	5.0 %

	Isostearyl Alcohol	5.0 %
	Kukui Nut Oil	2.0 %
	Dimethicone	1.0 %
	Fragrance (optional)	q.s.
5	Purified Water	q.s. ad 100.0 %

Heat a portion of the water to 65° - 70° C. Disperse the methyl paraben in the propylene glycol and add to the water with agitation. Add the urea and dissolve. Melt the Promulgen D, Arlacel, polyoxyl 40 stearate, isopropyl myristate, isostearyl alcohol, and kukui nut oil together at 65° - 70° C. Dissolve the propyl paraben in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the dimethicone and fragrance. Perform the final q.s. Rapidly cool to 40° C once the emulsion is formed. Continue mixing until room temperature is reached.

CREAM BASE WITH SENSATE EXAMPLE # 20

15	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
	Propylene Glycol	2.0 %
	Methyl paraben NF	0.2 %
	Propyl paraben NF	0.1 %
	Promulgen D	8.0 %
20	Polyoxyl 40 Stearate NF	4.0 %
	Arlacel 165	10.0 %
	Isopropyl Myristate	5.0 %
	Isostearyl Alcohol	5.0 %
	Kukui Nut Oil	2.0 %
25	Dimethicone	1.0 %
	Menthyl Lactate	2.0 %
	Fragrance (optional)	q.s.
	Purified Water	q.s. ad 100.0 %

Heat a portion of the water to 65° - 70° C. Disperse the methyl paraben in the propylene glycol and add to the water with agitation. Melt the Promulgen D, Arlacel, polyoxyl 40 stearate, isopropyl myristate, isostearyl alcohol, and kukui nut oil together at 65° - 70° C. Dissolve the propyl paraben in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the dimethicone, menthyl lactate, and fragrance. Perform the final q.s. Rapidly cool to 40° C once the emulsion is formed. Continue mixing until room temperature is reached.

CREAM BASE WITH ANALGESIC EXAMPLE # 21

	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
	Propylene Glycol	2.0 %
	Methyl paraben NF	0.2 %
5	Propyl paraben NF	0.1 %
	Promulgen D	8.0 %
	Polyoxyl 40 Stearate NF	4.0 %
	Arlacel 165	10.0 %
	Isopropyl Myristate	5.0 %
10	Isostearyl Alcohol	5.0 %
	Kukui Nut Oil	2.0 %
	Dimethicone	1.0 %
	Capsaicin Alkaloid	0.02 %
	Fragrance (optional)	q.s.
15	Purified Water	q.s. ad 100.0 %

- Heat a portion of the water to 65° - 70° C. Disperse the methyl paraben in the propylene glycol and add to the water with agitation. Melt the Promulgen D, Arlacel, polyoxyl 40 stearate, isopropyl myristate, isostearyl alcohol, and kukui nut oil together at 65° - 70° C. Dissolve the propyl paraben and the capsaicin in the oils.
- 20 Then add the oil phase to the water phase with rapid mixing. Remove heat and add the dimethicone and fragrance. Perform the final q.s. Rapidly cool to 40° C once the emulsion is formed. Continue mixing until room temperature is reached.

CREAM BASE WITH SENSATE EXAMPLE # 22

	<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
25	Propylene Glycol	2.0 %
	Methyl paraben NF	0.2 %
	Propyl paraben NF	0.1 %
	Promulgen D	8.0 %
30	Polyoxyl 40 Stearate NF	4.0 %
	Arlacel 165	10.0 %
	Isopropyl Myristate	5.0 %
	Isostearyl Alcohol	5.0 %
	Kukui Nut Oil	2.0 %
35	Dimethicone	1.0 %
	Methyl nicotinate	0.5 %

Fragrance (optional)	q.s.
Purified Water	q.s. ad 100.0 %

Heat a portion of the water to 65° - 70° C. Disperse the methyl paraben in the propylene glycol and add to the water with agitation. Melt the Promulgen D, Arlacel, polyoxyl 40 stearate, isopropyl myristate, isostearyl alcohol, and kukui nut oil together at 65°- 70° C. Dissolve the propyl paraben and the methyl nicotinate in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the dimethicone and fragrance. Perform the final q.s. Rapidly cool to 40° C once the emulsion is formed. Continue mixing until room temperature is reached.

CREAM BASE WITH HYDROCORTISONE & UREA EXAMPLE # 23

<u>Ingredients</u>	<u>Approximate Percent (w/w)</u>
Propylene Glycol	2.0 %
Hydrocortisone	1.0 %
Urea	4.0 %
Methyl paraben NF	0.2 %
Propyl paraben NF	0.1 %
Promulgen D	8.0 %
Polyoxyl 40 Stearate NF	4.0 %
Arlacel 165	10.0 %
Isopropyl Myristate	5.0 %
Isostearyl Alcohol	5.0 %
Kukui Nut Oil	2.0 %
Dimethicone	1.0 %
Fragrance (optional)	q.s.
Purified Water	q.s. ad 100.0 %

Heat a portion of the water to 65° - 70° C. Disperse the methyl paraben in the propylene glycol and add to the water with agitation. Add the urea and dissolve. Add the polyoxyl 40 stearate and dissolve. Add the hydrocortisone and disperse using a high shear mixer or similar. Melt the Promulgen D, Arlacel, , isopropyl myristate, isostearyl alcohol, and kukui nut oil together at 65°- 70° C. Dissolve the propyl paraben in the oils. Then add the oil phase to the water phase with rapid mixing. Remove heat and add the dimethicone and fragrance. Perform the final q.s. Rapidly cool to 40° C once the emulsion is formed. Continue mixing until room temperature is reached.

CLAIMS

What is claimed is:

1. A pharmaceutical composition comprising:
 - a) an effective amount of dermatopharmaceutical active agent,
 - 5 b) about 1.0% to about 10% of kukui nut oil by weight of the total composition, and
 - c) up to about 98% by weight of the total composition of a pharmaceutically acceptable base which comprises ingredients selected from the group consisting of propylene glycol, glycerin, xanthin gum, methyl paraben, propyl
 - 10 paraben, stearic acid, menthyl lactate, cetearyl alcohol (and) cetareth 20, polyoxyl 40 stearate, glyceryl stearate (and) PEG-100 stearate, isopropyl myristate, isopropyl alcohol, oleyl alcohol, oleic acid, dimethicone, or C₁₂-C₁₅ alcohols benzoate and purified water.
- 15 2. The composition according to claim 1 wherein the kukui nut oil is present at a concentration about 2% by weight of the total composition.
3. The composition according to claim 1 wherein the dermatopharmaceutical active agent is a corticosteroid, antibiotic, antihistamine, antifungal, anesthetic, or
 - 20 analgesic.
4. A pharmaceutical composition according to claim 1 which is
 - a) about 0.5% to 2.5% hydrocortisone,
 - b) about 2.0% kukui nut oil, and
 - 25 c) a pharmaceutically acceptable base comprising

propylene glycol	about 2.0 %
methyl paraben	about 0.2 %
propyl paraben	about 0.1 %
cetearyl alcohol (and) cetareth 20	about 8.0 %
30 polyoxyl 40 stearate	about 4.0 %
glyceryl stearate (and) PEG-100 stearate	about 10.0 %
isopropyl myristate	about 5.0 %
isostearyl alcohol	about 5.0 %
dimethicone	about 1.0 %
35 fragrance (optional)	q.s.
purified water	q.s. ad 100.0 %

5. A pharmaceutical composition according to claim 4 wherein the amount of hydrocortisone is 1.0 % by weight of the total composition.
6. A pharmaceutical composition according to claim 1 which is
- 5 a) about 0.5% to about 4% lidocaine hydrochloride,
 b) about 2.0% kukui nut oil, and
 c) a pharmaceutically acceptable base comprising
- | | |
|------------------------------------------|-------------------|
| propylene glycol | about 2.0 % |
| methyl paraben | about 0.2 % |
| 10 propyl paraben | about 0.1 % |
| cetearyl alcohol (and) cetareth 20 | about 4.0 - 6.0 % |
| polyoxyl 40 stearate | about 2.0 - 4.0% |
| glyceryl stearate (and) PEG-100 stearate | about 10.0 % |
| isopropyl myristate | about 5.0 % |
| 15 isostearyl alcohol | about 5.0 % |
| dimethicone | about 1.0 - 2.0 % |
| fragrance (optional) | q.s. |
| purified water | q.s. ad 100.0 %. |
- 20 7. A pharmaceutical composition according to claim 6 wherein the amount of lidocaine hydrochloride is 4.0% by weight of the total composition.
8. A pharmaceutical composition according to claim 1 which is
- 25 a) about 0.5% to 2.5% diphenhydramine hydrochloride,
 b) about 2.0% kukui nut oil, and
 c) a pharmaceutically acceptable base comprising
- | | |
|------------------------------------------|--------------|
| propylene glycol | about 2.0 % |
| methyl paraben | about 0.2 % |
| propyl paraben | about 0.1 % |
| 30 cetearyl alcohol (and) cetareth 20 | about 6.0 % |
| polyoxyl 40 stearate | about 4.0 % |
| glyceryl stearate (and) PEG-100 stearate | about 10.0 % |
| isopropyl myristate | about 5.0 % |
| isostearyl alcohol | about 5.0 % |
| 35 dimethicone | about 1.0 % |
| fragrance (optional) | q.s. |

purified water

q.s. ad 100.0 %.

9. A pharmaceutical composition according to claim 8 wherein the amount of diphenhydramine hydrochloride is 2.0 % by weight of the total composition.

5

10. A pharmaceutical composition according to claim 1 which is

- a) about 2.0% zinc oxide,
- b) about 2.0% of diphenhydramine hydrochloride,
- c) about 2.0% kukui nut oil, and
- 10 d) a pharmaceutically acceptable base comprising

propylene glycol	about 2.0 %
methyl paraben	about 0.2 %
propyl paraben	about 0.1 %
cetearyl alcohol (and) cetearth 20	about 6.0 %
15 polyoxyl 40 stearate	about 4.0 %
glyceryl stearate (and) PEG-100 stearate	about 10.0 %
isopropyl myristate	about 5.0 %
isostearyl alcohol	about 5.0 %
dimethicone	about 1.0 %
20 fragrance (optional)	q.s.
purified water	q.s. ad 100.0 %.

11. A pharmaceutical composition according to claim 1 which is

- a) about 10% urea,
- 25 b) about 2.0% kukui nut oil, and
- c) a pharmaceutically acceptable base comprising

propylene glycol	about 2.0 %
methyl paraben	about 0.2 %
propyl paraben	about 0.1 %
30 cetearyl alcohol (and) cetearth 20	about 8.0 %
polyoxyl 40 stearate	about 4.0 %
glyceryl stearate (and) PEG-100 stearate	about 10.0 %
isopropyl myristate	about 5.0 %
isostearyl alcohol	about 5.0 %
35 dimethicone	about 1.0 %
fragrance (optional)	q.s.

purified water

q.s. ad 100.0 %.

12. A pharmaceutical composition according to claim 1 which is

- | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| 5 | a) about 0.02% capsaicin alkaloid,
b) about 2.0% kukui nut oil, and
c) a pharmaceutically acceptable base comprising | |
| | propylene glycol | about 2.0 % |
| | methyl paraben | about 0.2 % |
| | propyl paraben | about 0.1 % |
| 10 | cetearyl alcohol (and) cetareth 20
polyoxyl 40 stearate
glyceryl stearate (and) PEG-100 stearate
isopropyl myristate
isostearyl alcohol | about 8.0 %
about 4.0 %
about 10.0 %
about 5.0 %
about 5.0 % |
| 15 | dimethicone
fragrance (optional)
purified water | about 1.0 %
q.s.
q.s. ad 100.0 %. |

13. A pharmaceutical composition according to claim 1 which is

- | | | |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| 20 | a) about 1.0% of hydrocortisone,
b) about 4.0% of urea,
c) about 2.0% kukui nut oil, and
d) a pharmaceutically acceptable base comprising | |
| | propylene glycol | about 2.0 % |
| 25 | methyl paraben
propyl paraben
cetearyl alcohol (and) cetareth 20
polyoxyl 40 stearate
glyceryl stearate (and) PEG-100 stearate
isopropyl myristate
isostearyl alcohol
dimethicone
fragrance (optional)
purified water | about 0.2 %
about 0.1 %
about 8.0 %
about 4.0 %
about 10.0 %
about 5.0 %
about 5.0 %
about 1.0 %
q.s.
q.s. ad 100.0 %. |

35

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/18981

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K7/48 A61K35/78

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
------------	------------------------------------------------------------------------------------	-----------------------

A	WO 85 00746 A (TUTSKY) 28 February 1985 see the whole document & US 4 525 344 A cited in the application ---	1-13
A	DE 44 05 127 A (HENKEL) 31 August 1995 see the whole document ---	1-13
A	US 5 279 817 A (FRANCO) 18 January 1994 see the whole document ---	1-13
A	US 4 154 823 A (SCHUTT) 15 May 1979 see the whole document ---	1-13

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

19 January 1998

Date of mailing of the international search report

30/01/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Fischer, J.P.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/18981

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p> DATABASE WPI Week 9514 Derwent Publications Ltd., London, GB; AN 95-101776 XP002052527 & JP 07 025 741 A (SANSEI SEIYAKU KK) see abstract ----- </p>	1-13

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/18981

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8500746 A	28-02-85	US 4525344 A AU 572559 B AU 3310484 A BR 8407016 A CA 1244350 A DK 165185 A EP 0153373 A JP 60502004 T US 4784849 A	25-06-85 12-05-88 12-03-85 02-07-85 08-11-88 14-06-85 04-09-85 21-11-85 15-11-88
DE 4405127 A	31-08-95	WO 9522312 A EP 0744936 A JP 9508910 T	24-08-95 04-12-96 09-09-97
US 5279817 A	18-01-94	NONE	
US 4154823 A	15-05-79	NONE	